Enrolling



A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma (MM)^{1,2}

Elranatamab is an investigational compound.


These are not the complete inclusion/exclusion criteria. This information is current as of April 2022.

KEY INCLUSION CRITERIA:

- MM diagnosis as defined according to International Myeloma Working Group (IMWG)
- Age ≥18 years
- Relapsed/refractory MM with ≥3 prior lines of therapy
- Refractory to ≥1 immunomodulatory drug (IMiD), ≥1 proteasome inhibitor (PI), and ≥1 anti-CD38 monoclonal antibody (mAb)
- Eastern Cooperative Oncology Group (ECOG)
 Performance Status 0-1
- Adequate renal, hepatic, cardiac, and bone marrow function

KEY EXCLUSION CRITERIA:

- Active plasma cell leukemia
- Amyloidosis
- Stem cell transplant within 12 weeks prior to enrollment, or active Graft Versus Host Disease (GVHD)
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome
- Active, uncontrolled bacterial, fungal or viral infection
- Previous treatment with BCMA-bispecific antibody (sub-study A)
- Previous treatment with BCMA-directed therapy (sub-study B)



PRIMARY ENDPOINTS:

SUB-STUDY A:

- Dose limiting toxicity (Phase 1)
- Objective response rate (Phase 2)

SUB-STUDY B:

- Dose limiting toxicity (Phase 1 escalation)
- Frequency of treatment-emergent adverse events (Phase 1 expansion)
- Frequency of laboratory abnormalities (Phase 1 expansion)

Learn more at ClinicalTrials.gov



NCT05090566